Novo Nordisk stated that Wegovy HDs accelerated approval by the FDA was based on a 72-week study that showed an average weight loss of about 20.7% in patients
Patients on tirzepatide and semaglutide frequently report transformative weight loss that improves their quality of life and overall health
Only a qualified healthcare provider can evaluate your specific medical situation, taking into account your medical history, conducting appropriate tests, and providing personalized advice and recommendations
Semaglutide for Weight Loss: Clinical Trials and Findings The clinical evidence from these trials underscores semaglutides effectiveness as a transformative weight-loss solution
Wegovy is also the only oral GLP-1 FDA-approved specifically for weight loss, whereas Rybelsus is only approved for type 2 diabetes
Exposure to improper temperatures, especially higher ones, can turn your medication into a breeding ground for harmful microorganisms